Zobrazeno 1 - 10
of 195
pro vyhledávání: '"J. De Langen"'
Autor:
Tanja D de Gruijl, Rieneke van de Ven, Geke A P Hospers, Marc C Huisman, Gerben J C Zwezerijnen, C Willemien Menke-van der Houven van Oordt, Iris H C Miedema, Johanna E. E. Pouw, Anne Kwakman, Florentine E F Timmer, Adrianus J de Langen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 6 (2024)
Introduction Immune checkpoint inhibitors (ICIs) can elicit anticancer immune responses, but predictive biomarkers are needed. We measured programmed death ligand 1 (PD-L1) expression in organs and lymph nodes using 18F-BMS-986192 positron emission t
Externí odkaz:
https://doaj.org/article/25fc274b5a5a47a2b15beea98d6e7ced
Autor:
Frank J. Borm, Jasper Smit, Joyce Bakker, Maurits Wondergem, Egbert F. Smit, Adrianus J. de Langen, Tanja D. de Gruijl
Publikováno v:
OncoImmunology, Vol 12, Iss 1 (2023)
ABSTRACTBetter biomarkers for programmed death - (ligand) 1 (PD-(L)1) checkpoint blockade in non-small cell lung cancer (NSCLC) are needed. We explored the predictive value of early response evaluation using Fluor-18-deoxyglucose positron emission to
Externí odkaz:
https://doaj.org/article/b3bac891f09a4fdfb2e410416d7ae4df
Autor:
Marinda Meertens, M. Benthe Muntinghe-Wagenaar, Barend J. Sikkema, Marta Lopez-Yurda, Valesca P. Retèl, Marthe S. Paats, Rob Ter Heine, Ed Schuuring, Wim Timens, Daan J. Touw, Job F. M. van Boven, Adrianus. J. de Langen, Sayed M. S. Hashemi, Lizza E. L. Hendriks, Sander Croes, Michel M. van den Heuvel, Anne-Marie C. Dingemans, Ron H. J. Mathijssen, Egbert F. Smit, Alwin D. R. Huitema, Neeltje Steeghs, Anthonie J. van der Wekken
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundAlectinib is first-line therapy in patients with stage IV non-small cell lung carcinoma (NSCLC) and an anaplastic lymphoma kinase (ALK) fusion. A shorter median progression-free survival (mPFS) was observed when alectinib minimum plasma con
Externí odkaz:
https://doaj.org/article/4457ff0cdd7b4bd9aa0922759784c7a7
Autor:
Iris H. C. Miedema, Jessica E. Wijngaarden, Johanna E. E. Pouw, Gerben J. C. Zwezerijnen, Hylke J. Sebus, Egbert Smit, Adrianus J. de Langen, Idris Bahce, Andrea Thiele, Daniëlle J. Vugts, Ronald Boellaard, Marc C. Huisman, C. Willemien Menke-van der Houven van Oordt
Publikováno v:
Cancers, Vol 15, Iss 23, p 5546 (2023)
Introduction: 89Zr-immuno-PET (positron emission tomography with zirconium-89-labeled monoclonal antibodies ([89Zr]Zr-mAbs)) can be used to study the biodistribution of mAbs targeting the immune system. The measured uptake consists of target-specific
Externí odkaz:
https://doaj.org/article/b52fe6e2c6ae474898fc085a9d717c69
Autor:
Evert S.M. van Aken, Yvette M. van der Linden, Johannes V. van Thienen, Adrianus J. de Langen, Corrie A.M. Marijnen, Monique C. de Jong
Publikováno v:
Clinical and Translational Radiation Oncology, Vol 33, Iss , Pp 93-98 (2022)
Introduction: With the introduction of tyrosine kinase inhibitors and systemic antibodies, including immune checkpoint inhibitors, the survival of advanced-stage cancer patients has improved for many tumor types. These patients are increasingly refer
Externí odkaz:
https://doaj.org/article/2ee274ebaf744dcea799d6ec62a579d0
Autor:
Liesbeth M. Hondelink, MD, Merel Jebbink, MD, Jan H. von der Thüsen, MD, PhD, Danielle Cohen, MD, PhD, Hendrikus J. Dubbink, PhD, Marthe S. Paats, MD, PhD, Anne-Marie C. Dingemans, MD, PhD, Adrianus J. de Langen, MD, PhD, Mirjam C. Boelens, PhD, Egbert F. Smit, MD, PhD, Pieter E. Postmus, MD, PhD, Tom van Wezel, PhD, Kim Monkhorst, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 12, Pp 100252- (2021)
Introduction: With the approval of first-line osimertinib treatment in stage IV EGFR-mutated NSCLC, detection of resistance mechanisms will become increasingly important—and complex. Clear guidelines for analyses of these resistance mechanisms are
Externí odkaz:
https://doaj.org/article/15653a46b49e44dca1398d582c62eabe
Autor:
Sophie M. Ernst, Joanne M. Mankor, Job van Riet, Jan H. von der Thüsen, Hendrikus J. Dubbink, Joachim G.J.V. Aerts, Adrianus J. de Langen, Egbert F. Smit, Anne-Marie C. Dingemans, Kim Monkhorst
Publikováno v:
Journal of Thoracic Oncology, 18(4), 487-498. International Association for the Study of Lung Cancer
Introduction: Patient-reported smoking history is frequently used as a stratification factor in NSCLC-directed clinical research. Nevertheless, this classification does not fully reflect the mutational processes in a tumor. Next-generation sequencing
Autor:
Guilherme D. Kolinger, David Vállez García, Gerbrand M. Kramer, Virginie Frings, Egbert F. Smit, Adrianus J. de Langen, Rudi A. J. O. Dierckx, Otto S. Hoekstra, Ronald Boellaard
Publikováno v:
EJNMMI Research, Vol 9, Iss 1, Pp 1-12 (2019)
Abstract Background Total metabolic active tumour volume (TMATV) and total tumour burden (TTB) are increasingly studied as prognostic and predictive factors in non-small cell lung cancer (NSCLC) patients. In this study, we investigated the repeatabil
Externí odkaz:
https://doaj.org/article/3d713e086e37471f9cb28544adbb8e47
Autor:
Eveline Annette van de Stadt, Maqsood Yaqub, Robert C. Schuit, Imke H. Bartelink, Anke F. Leeuwerik, Lothar A. Schwarte, Adrianus J. de Langen, Harry Hendrikse, Idris Bahce
Publikováno v:
Diagnostics, Vol 12, Iss 4, p 883 (2022)
Background: Patients with non-small cell lung cancer (NSCLC) driven by activating epidermal growth factor receptor (EGFR) mutations are best treated with therapies targeting EGFR, i.e., tyrosine kinase inhibitors (TKI). Radiolabeled EGFR-TKI and PET
Externí odkaz:
https://doaj.org/article/64b638caa8ad4002ad214b3cb07f37f1
Autor:
A. N. Niemeijer, D. Leung, M. C. Huisman, I. Bahce, O. S. Hoekstra, G. A. M. S. van Dongen, R. Boellaard, S. Du, W. Hayes, R. Smith, A. D. Windhorst, N. H. Hendrikse, A. Poot, D. J. Vugts, E. Thunnissen, P. Morin, D. Lipovsek, D. J. Donnelly, S. J. Bonacorsi, L. M. Velasquez, T. D. de Gruijl, E. F. Smit, A. J. de Langen
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-5 (2018)
Assessment of PD-1 and PD-L1 expression can be predictive of immunotherapy response in lung cancer. Here the authors assess the clinical toxicity, safety and quality of non-invasive imaging of PD-1 and PD-L1 expression in 13 patients with advanced lu
Externí odkaz:
https://doaj.org/article/d775b429652c43478095f6b7bc6015c1